INNOVATE BIOPHARMACEUTICLS
Reported by NEW YORK STATE COMMON RETIREMENT FUND
Reported 0 shares, down 20,600 (100.0%) from the prior quarter.
Reported value -100.0%; share count -100.0% vs. the prior quarter.
Reported position value by quarter
Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.
| Date | Holding Value |
|---|
Quarterly position history
How this manager's reported quarter-end position changed over time.
| Quarter | Activity | Shares | Change | % of reported 13F | Reported value | Filed | Source filing |
|---|---|---|---|---|---|---|---|
|
This position's reported history falls outside the five-year preview window. A free account unlocks it.
Unlock full history
|
|||||||
Who else reported the position
42 managers reported INNOVATE BIOPHARMACEUTICLS for Q2 2019.
| Manager | Activity | Shares | Change | % of reported 13F | Reported value | Tenure |
|---|---|---|---|---|---|---|
| SABBY MANAGEMENT LLC | New | 1,336,248 | +1,336,248 | 1.95% | $1,550,000 | 1 qtr |
| VANGUARD GROUP INC | Added | 955,144 | +121,104 | < 0.01% | $1,108,000 | 5 qtrs |
| BlackRock Inc | Reduced | 346,790 | -862,072 | < 0.01% | $402,000 | 6 qtrs |
| NORTHERN TRUST CORPORATION | Reduced | 193,464 | -26,146 | < 0.01% | $224,000 | 5 qtrs |
| GEODE CAPITAL MANAGEMENT LLC | Reduced | 116,630 | -60,628 | < 0.01% | $135,000 | 5 qtrs |
| MILLENNIUM MANAGEMENT LLC | New | 95,262 | +95,262 | < 0.01% | $111,000 | 1 qtr |
| Paloma Partners Management Co | New | 89,694 | +89,694 | < 0.01% | $104,000 | 1 qtr |
| MORGAN STANLEY | Added | 72,562 | +2,714 | < 0.01% | $84,000 | 6 qtrs |
| GSA CAPITAL PARTNERS LLP | Added | 64,786 | +24,186 | < 0.01% | $75,000 | 3 qtrs |
| Virtu Financial LLC | New | 62,822 | +62,822 | < 0.01% | $73,000 | 1 qtr |
Filing details and methodology As reported
- Report period
- June 30, 2019
- Filed
- August 09, 2019
- Filing type
- 13F-HR
- Position type
- Common Stock
Voting authority reported
No voting-authority amounts were reported for this position. Voting authority is not required for reported call options.
Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.